Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$0.38 USD
-0.02 (-4.90%)
Updated May 15, 2024 03:57 PM ET
After-Market: $0.39 +0.01 (1.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 181 - 192 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Exclusive Non-Invasive Companion Diagnostic for Aramchol; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: CHEN Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Clearing Up Fat and Inflammation Safely in NASH; Initiate with Buy and $21 Price Target
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: CHEN Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
We are initiating coverage with a Buy rating and 12-month price target of $20/share.
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E